Treatment of idiopathic pulmonary fibrosis

Semin Respir Crit Care Med. 2006 Dec;27(6):668-76. doi: 10.1055/s-2006-957338.


Idiopathic pulmonary fibrosis (IPF) is a relentlessly progressive lung disease in most cases, and effective treatment is still lacking. This review examines the current status of treatment options and complexities in the management of patients with IPF. Although optimal therapy for IPF has not been identified, ongoing research efforts warrant reason for optimism. Current management of IPF includes not only judicious use of available pharmacological agents tailored to individual circumstances but also patient education through realistic assessment of prognosis, discussion of pros and cons of pharmacotherapy, early consideration of lung transplantation when applicable, treatment of complications, supportive care, and encouragement to participate in clinical trials.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Adrenal Cortex Hormones / therapeutic use
  • Gastroesophageal Reflux / complications
  • Humans
  • Immunosuppressive Agents / classification
  • Immunosuppressive Agents / therapeutic use
  • Lung Transplantation
  • Pulmonary Fibrosis / complications
  • Pulmonary Fibrosis / therapy*
  • Risk Factors


  • Adrenal Cortex Hormones
  • Immunosuppressive Agents